EA201892619A1 - Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 - Google Patents
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2Info
- Publication number
- EA201892619A1 EA201892619A1 EA201892619A EA201892619A EA201892619A1 EA 201892619 A1 EA201892619 A1 EA 201892619A1 EA 201892619 A EA201892619 A EA 201892619A EA 201892619 A EA201892619 A EA 201892619A EA 201892619 A1 EA201892619 A1 EA 201892619A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mutant
- polypeptide
- affinity
- immunoconjugate
- polypetips
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 title abstract 7
- 102000000588 Interleukin-2 Human genes 0.000 title abstract 7
- 229940127121 immunoconjugate Drugs 0.000 title abstract 4
- 230000035772 mutation Effects 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 108700004922 F42A Proteins 0.000 abstract 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 abstract 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102220505697 Palmitoyl-protein thioesterase 1_Y45F_mutation Human genes 0.000 abstract 1
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 abstract 1
- 102220610852 Thialysine N-epsilon-acetyltransferase_L72G_mutation Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Abstract
В заявке описан иммуноконъюгат, содержащий мутантный полипептид интерлейкина-2 (IL-2) с тремя аминокислотными мутациями, соответствующими аминокислотным заменам F42A, Y45A и L72G в последовательности человеческого IL-2 (SEQ ID NO:1), где указанные мутации аннулируют или снижают аффинность мутантного полипептида IL-2 к высокоаффинному рецептору IL-2 и сохраняют аффинность мутантного полипептида IL-2 к рецептору IL-2 с промежуточной аффинностью по сравнению с полипептидом IL-2 дикого типа. Кроме того, в заявке описаны выделенный полинуклеотид, кодирующий, указанный иммуноконъюгат, эксперессионный вектор и клетки-хозяева, содержащие этот выделенный полинуклеотид. В ней также раскрыты способ получения иммуноконъюгата, содержащие его фармацевтические композиции, способы лечения рака и стимуляции иммунной системы, в которых применяются эти композиции.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11164237 | 2011-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201892619A1 true EA201892619A1 (ru) | 2019-04-30 |
Family
ID=46022216
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201892619A EA201892619A1 (ru) | 2011-04-29 | 2012-02-07 | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
EA201301208A EA025851B1 (ru) | 2011-04-29 | 2012-04-26 | Новые иммуноконъюгаты |
EA201600418A EA034251B1 (ru) | 2011-04-29 | 2012-04-26 | Новые иммуноконъюгаты |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201301208A EA025851B1 (ru) | 2011-04-29 | 2012-04-26 | Новые иммуноконъюгаты |
EA201600418A EA034251B1 (ru) | 2011-04-29 | 2012-04-26 | Новые иммуноконъюгаты |
Country Status (34)
Country | Link |
---|---|
US (6) | US9447159B2 (ru) |
EP (1) | EP2702074B1 (ru) |
JP (3) | JP5972355B2 (ru) |
KR (1) | KR101715445B1 (ru) |
CN (2) | CN103649114B (ru) |
AR (1) | AR086075A1 (ru) |
AU (2) | AU2012247548B2 (ru) |
BR (1) | BR112013025127A2 (ru) |
CA (1) | CA2831008C (ru) |
CL (1) | CL2013003064A1 (ru) |
CO (1) | CO6801645A2 (ru) |
CR (1) | CR20130480A (ru) |
DK (1) | DK2702074T3 (ru) |
EA (3) | EA201892619A1 (ru) |
EC (1) | ECSP13013002A (ru) |
ES (1) | ES2707297T3 (ru) |
HK (1) | HK1259474A1 (ru) |
HR (1) | HRP20190118T1 (ru) |
HU (1) | HUE042187T2 (ru) |
IL (2) | IL229006B (ru) |
LT (1) | LT2702074T (ru) |
MX (2) | MX354868B (ru) |
MY (2) | MY164661A (ru) |
PE (2) | PE20181202A1 (ru) |
PL (1) | PL2702074T3 (ru) |
PT (1) | PT2702074T (ru) |
RS (1) | RS58295B1 (ru) |
SG (2) | SG194465A1 (ru) |
SI (1) | SI2702074T1 (ru) |
TR (1) | TR201818974T4 (ru) |
TW (1) | TWI592424B (ru) |
UA (1) | UA115034C2 (ru) |
WO (1) | WO2012146628A1 (ru) |
ZA (1) | ZA201306820B (ru) |
Families Citing this family (171)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2767392C (en) | 2009-07-06 | 2017-03-14 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
CA2840079C (en) * | 2010-07-06 | 2018-07-03 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
JP5953303B2 (ja) | 2010-07-29 | 2016-07-20 | ゼンコア インコーポレイテッド | 改変された等電点を有する抗体 |
UA113712C2 (xx) | 2010-08-13 | 2017-02-27 | Антитіло до fap і способи його застосування | |
CA2862864C (en) | 2011-01-13 | 2018-12-11 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
JP5878182B2 (ja) | 2011-02-10 | 2016-03-08 | ロシュ グリクアート アーゲー | ミュータントインターロイキン−2ポリペプチド |
ES2657856T3 (es) * | 2011-03-02 | 2018-03-07 | Roche Glycart Ag | Anticuerpos CEA |
DK2691417T3 (en) | 2011-03-29 | 2018-11-19 | Roche Glycart Ag | ANTIBODY FC VARIANTS |
CN103533951B (zh) | 2011-04-08 | 2017-04-19 | 安姆根有限公司 | 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
JP6159724B2 (ja) | 2011-08-23 | 2017-07-05 | ロシュ グリクアート アーゲー | T細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法 |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
US20140356399A1 (en) | 2012-01-12 | 2014-12-04 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
US9714276B2 (en) | 2012-01-26 | 2017-07-25 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) polypeptides |
WO2013111012A2 (en) | 2012-01-27 | 2013-08-01 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
PL3495387T3 (pl) | 2012-07-13 | 2022-01-10 | Roche Glycart Ag | Dwuswoiste przeciwciała anty-VEGF/anty-ANG-2 i ich zastosowanie w leczeniu chorób naczyniowych oka |
SG11201407580YA (en) | 2012-08-07 | 2014-12-30 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
WO2014023673A1 (en) | 2012-08-08 | 2014-02-13 | Roche Glycart Ag | Interleukin-10 fusion proteins and uses thereof |
US20140044675A1 (en) * | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
EP2953972B1 (en) | 2013-02-05 | 2020-07-08 | EngMab Sàrl | Method for the selection of antibodies against bcma |
MX2015010350A (es) | 2013-02-26 | 2015-10-29 | Roche Glycart Ag | Moleculas de union a antigeno biespecificas que activan la celula t. |
EA201891502A1 (ru) | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
JP6509852B2 (ja) * | 2013-07-31 | 2019-05-08 | アムジエン・インコーポレーテツド | 増殖分化因子15(gdf−15)の構築物 |
WO2015091656A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE |
MX2016008631A (es) * | 2014-01-08 | 2016-12-20 | Shanghai hengrui pharmaceutical co ltd | Proteina heterodimérica il-5 y usos de la misma. |
CN113637692A (zh) | 2014-01-15 | 2021-11-12 | 卡德门企业有限公司 | 免疫调节剂 |
MX370283B (es) * | 2014-02-06 | 2019-12-09 | Hoffmann La Roche | Proteinas de fusion de interleucina-2 y usos de las mismas. |
CN106061997A (zh) * | 2014-02-06 | 2016-10-26 | 豪夫迈·罗氏有限公司 | 白介素‑10免疫缀合物 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
AU2015237184B2 (en) | 2014-03-28 | 2020-11-26 | Xencor, Inc. | Bispecific antibodies that bind to CD38 and CD3 |
AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
DK3172227T3 (da) * | 2014-07-21 | 2019-12-02 | Delinia Inc | Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme |
KR102317315B1 (ko) | 2014-08-04 | 2021-10-27 | 에프. 호프만-라 로슈 아게 | 이중특이적 t 세포 활성화 항원 결합 분자 |
CN107106654B (zh) | 2014-08-11 | 2021-06-11 | 德里尼亚公司 | 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体 |
SG11201701157UA (en) * | 2014-08-29 | 2017-03-30 | Hoffmann La Roche | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
CN107074966A (zh) * | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 具有改变的FCRN‑和蛋白A‑结合性质的Fc区变体 |
ES2835823T3 (es) | 2014-11-20 | 2021-06-23 | Hoffmann La Roche | Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1 |
CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
MY184268A (en) | 2014-11-26 | 2021-03-30 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
JP6621478B2 (ja) | 2014-12-19 | 2019-12-18 | アルカーメス,インコーポレイテッド | 一本鎖Fc融合タンパク質 |
US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
PL3313877T3 (pl) | 2015-06-24 | 2020-11-02 | F. Hoffmann-La Roche Ag | Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
KR20180073561A (ko) | 2015-10-02 | 2018-07-02 | 에프. 호프만-라 로슈 아게 | 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자 |
AU2016329120B2 (en) | 2015-10-02 | 2023-04-13 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for a costimulatory TNF receptor |
SG11201804259UA (en) | 2015-12-04 | 2018-06-28 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
CN108290954B (zh) | 2015-12-09 | 2022-07-26 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于降低抗药物抗体形成 |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
CN108368179B (zh) | 2016-01-08 | 2022-08-23 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法 |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
SI3433280T1 (sl) | 2016-03-22 | 2023-07-31 | F. Hoffmann-La Roche Ag | S proteazo aktivirane bispecifične molekule celic T |
EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DISEASES |
EP4257613A3 (en) | 2016-06-14 | 2023-12-13 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
JP7084881B2 (ja) | 2016-06-22 | 2022-06-15 | アルカームス インコーポレーテッド | Il-10の免疫刺激特性および抗炎症特性を調節するための組成物および方法 |
JP7021127B2 (ja) | 2016-06-28 | 2022-02-16 | ゼンコア インコーポレイテッド | ソマトスタチン受容体2に結合するヘテロ二量体抗体 |
US10696722B2 (en) | 2016-08-10 | 2020-06-30 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP7022123B2 (ja) | 2016-09-30 | 2022-02-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Cd3に対する二重特異性抗体 |
WO2018071919A1 (en) | 2016-10-14 | 2018-04-19 | Xencor, Inc. | IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS |
IL266112B1 (en) | 2016-10-17 | 2024-03-01 | Pfizer | Antibodies against EDB and antibody-drug conjugates |
EP3529350A1 (en) * | 2016-10-19 | 2019-08-28 | H. Hoffnabb-La Roche Ag | Method for producing an immunoconjugate |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
EA201991142A1 (ru) | 2016-11-08 | 2019-10-31 | Варианты il-2 для лечения аутоиммунных заболеваний | |
CN110691613B (zh) * | 2017-01-03 | 2023-12-08 | 财团法人卫生研究院 | 增强免疫反应的组合物及方法 |
IL268660B2 (en) * | 2017-02-17 | 2024-03-01 | Denali Therapeutics Inc | Polypeptides that bind to a transgenic transferrin receptor, polynucleotides encoding them, methods for their preparation and use |
KR102619015B1 (ko) * | 2017-03-15 | 2023-12-28 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
DK3606946T3 (da) | 2017-04-03 | 2022-10-24 | Hoffmann La Roche | Immunkonjugater af et anti-PD-1-antistof med et muteret IL-2 eller med IL-15 |
EP3606947B1 (en) * | 2017-04-03 | 2022-12-21 | F. Hoffmann-La Roche AG | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
WO2018189220A1 (en) | 2017-04-13 | 2018-10-18 | F. Hoffmann-La Roche Ag | An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
JP2020523319A (ja) * | 2017-06-07 | 2020-08-06 | シルバーバック セラピューティックス インコーポレイテッド | 免疫調節化合物の抗体コンジュゲートおよびその使用 |
EP3645122A1 (en) | 2017-06-30 | 2020-05-06 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
PT3661954T (pt) | 2017-08-03 | 2022-04-14 | Amgen Inc | Muteínas de interleuquina-21 e métodos de tratamento |
JP2020529976A (ja) | 2017-08-03 | 2020-10-15 | シンソークス,インク. | 自己免疫疾患の処置のためのサイトカイン抱合体 |
CN111094336A (zh) * | 2017-08-10 | 2020-05-01 | 戴纳立制药公司 | 使用转铁蛋白受体结合蛋白的基于亲和力的方法 |
JP2020535145A (ja) * | 2017-09-25 | 2020-12-03 | ディンフー バイオターゲット カンパニー リミテッド | 癌治療のための方法及び組成物 |
CN111278859A (zh) | 2017-10-02 | 2020-06-12 | 戴纳立制药公司 | 包含酶替代疗法酶的融合蛋白 |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CA3082383A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
JP7163399B2 (ja) * | 2017-11-20 | 2022-10-31 | 泰州▲邁▼博太科▲薬▼▲業▼有限公司 | Cd47とpd-l1を標的にする二重機能の融合タンパク質 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
KR20200100098A (ko) | 2017-12-19 | 2020-08-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
SG11202005605SA (en) | 2018-01-12 | 2020-07-29 | Amgen Inc | Anti-pd-1 antibodies and methods of treatment |
WO2019152979A1 (en) | 2018-02-05 | 2019-08-08 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
WO2019173832A2 (en) * | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
EA202092419A1 (ru) | 2018-04-09 | 2021-02-05 | Эмджен Инк. | Слитые белки ростового фактора дифференцировки 15 |
EP3781598A1 (en) * | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
EP3781599A1 (en) * | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
US20190352362A1 (en) * | 2018-04-18 | 2019-11-21 | Xencor, Inc. | LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS |
EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
CA3086486A1 (en) * | 2018-09-17 | 2020-03-26 | Gi Innovation, Inc. | Fusion protein comprising il-2 protein and cd80 protein, and use thereof |
AR114732A1 (es) | 2018-09-18 | 2020-10-07 | Hoffmann La Roche | Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco |
CN112955468A (zh) * | 2018-10-01 | 2021-06-11 | 豪夫迈·罗氏有限公司 | 包含抗fap克隆212的双特异性抗原结合分子 |
MA53822A (fr) | 2018-10-03 | 2021-08-11 | Xencor Inc | Protéines de fusion fc hétérodimères d'il -12 |
US11377477B2 (en) | 2018-10-12 | 2022-07-05 | Xencor, Inc. | PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof |
EP3870598A1 (en) | 2018-10-23 | 2021-09-01 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
CA3119049A1 (en) * | 2018-11-09 | 2020-05-14 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent |
EP3880698A4 (en) * | 2018-11-14 | 2022-11-30 | RubrYc Therapeutics, Inc. | MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF |
US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
US11608376B2 (en) | 2018-12-21 | 2023-03-21 | Hoffmann-La Roche Inc. | Tumor-targeted agonistic CD28 antigen binding molecules |
CN113286822A (zh) * | 2018-12-21 | 2021-08-20 | 豪夫迈·罗氏有限公司 | 靶向肿瘤的超激动性cd28抗原结合分子 |
WO2020148612A1 (en) | 2019-01-14 | 2020-07-23 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
CN114173875A (zh) | 2019-03-01 | 2022-03-11 | Xencor股份有限公司 | 结合enpp3和cd3的异二聚抗体 |
EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | ANTI-MADCAM IMMUNE TOLERANCE |
JP2022533254A (ja) * | 2019-05-24 | 2022-07-21 | プロヴィヴァ セラピューティクス (ホン コン) リミテッド | Il-2組成物およびその使用方法 |
EP3983432A1 (en) | 2019-06-12 | 2022-04-20 | Askgene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
WO2020249757A1 (en) * | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
TW202115115A (zh) | 2019-07-02 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | 免疫結合物 |
TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
BR112022012112A2 (pt) * | 2019-12-20 | 2022-09-06 | Regeneron Pharma | Agonistas de il2 e métodos de uso dos mesmos |
AU2020411480B2 (en) | 2019-12-23 | 2023-12-21 | Denali Therapeutics Inc. | Progranulin variants |
US20210252142A1 (en) * | 2020-02-06 | 2021-08-19 | Aetio Biotherapy, Inc. | Compositions and methods for treating viral infections |
US11365233B2 (en) | 2020-04-10 | 2022-06-21 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
IL294451A (en) | 2020-04-15 | 2022-09-01 | Hoffmann La Roche | immune conjugates |
IL298007A (en) | 2020-05-12 | 2023-01-01 | Regeneron Pharma | Novel il10 agonists and methods of using them |
GB2621482A (en) | 2020-05-13 | 2024-02-14 | Bonum Therapeutics Inc | Compositions of protein complexes and methods of use thereof |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
AU2021291011A1 (en) | 2020-06-19 | 2023-01-05 | F. Hoffmann-La Roche Ag | Antibodies binding to CD3 and CD19 |
US20230416363A1 (en) * | 2020-06-23 | 2023-12-28 | Kadmon Corporation, Llc | Anti-PD-1 Antibodies and Fusion Proteins |
WO2022035200A1 (ko) * | 2020-08-11 | 2022-02-17 | 주식회사 카나프테라퓨틱스 | Il-12 및 항-cd20 항체를 포함하는 융합단백질 및 이의 용도 |
KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
US11865082B2 (en) | 2020-09-09 | 2024-01-09 | Hoffmann-La Roche Inc. | Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1 |
JP2023548045A (ja) * | 2020-10-23 | 2023-11-15 | アッシャー バイオセラピューティクス, インコーポレイテッド | 免疫細胞機能をモジュレートするためのcd8抗原結合分子を有する融合物 |
IL303745A (en) * | 2020-12-17 | 2023-08-01 | Ose Immunotherapeutics | Bifunctional ANTI-PD1/IL-7 molecules |
WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
EP4281549A1 (en) * | 2021-01-19 | 2023-11-29 | Seneca Therapeutics, Inc. | Armed seneca valley virus oncolytic therapy compositions and methods thereof |
CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
JP2024512382A (ja) | 2021-03-09 | 2024-03-19 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-1標的化il-2バリアント免疫コンジュゲートと抗tyrp1/抗cd3二重特異性抗体の併用療法 |
JP2024508949A (ja) | 2021-03-09 | 2024-02-28 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-1標的化il-2変異体イムノコンジュゲートとfap/4-1bb結合分子との併用療法 |
KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
KR20230157448A (ko) | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
JP2024511465A (ja) | 2021-03-26 | 2024-03-13 | イナート・ファルマ・ソシエテ・アノニム | Nk細胞エンゲージングのためにサイトカインに融合したnkp46結合性部位、がん抗原結合性部位を含む多特異性タンパク質 |
CA3213917A1 (en) * | 2021-04-09 | 2022-10-13 | Nicolas Poirier | New scaffold for bifunctional molecules with improved properties |
BR112023025476A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína de ligação multimérica e seu método de produção, composição farmacêutica, molécula de ácido nucleico isolada, vetor de expressão, célula isolada e proteína de ligação para uso |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
WO2022258662A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
WO2023062050A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | New interleukin-7 immunoconjugates |
WO2023062048A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | Alternative pd1-il7v immunoconjugates for the treatment of cancer |
WO2023078245A1 (zh) * | 2021-11-02 | 2023-05-11 | 广东菲鹏制药股份有限公司 | Il10单体融合蛋白及其应用 |
WO2023094569A1 (en) | 2021-11-26 | 2023-06-01 | F. Hoffmann-La Roche Ag | Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies |
WO2023153880A1 (ko) * | 2022-02-11 | 2023-08-17 | 주식회사 카나프테라퓨틱스 | Il-12 및 항-fap 항체를 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물 |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1156905B (it) | 1977-04-18 | 1987-02-04 | Hitachi Metals Ltd | Articolo di ornamento atto ad essere fissato mediante un magnete permanente |
WO1985000817A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
GB9317423D0 (en) | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
IT1282692B1 (it) * | 1996-02-27 | 1998-03-31 | San Raffaele Centro Fond | Citochine modificate per l'uso in terapia |
DE19607751A1 (de) | 1996-02-29 | 1997-09-04 | Henkel Kgaa | Neue Aminophenol-Derivate und deren Verwendung |
AU4982097A (en) | 1996-10-18 | 1998-05-15 | Board Of Regents, The University Of Texas System | Anti-erbb2 antibodies |
US6417337B1 (en) | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
HUP0100813A3 (en) | 1998-02-25 | 2003-08-28 | Lexigen Pharmaceuticals Corp L | Enhancing the circulating half-life of antibody-based fusion proteins |
WO1999043817A1 (en) | 1998-02-25 | 1999-09-02 | The Dow Chemical Company | High affinity humanized anti-cea monoclonal antibodies |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
FR2783605A1 (fr) | 1998-09-23 | 2000-03-24 | Digibio | Procede, systeme et dispositif pour produire a partir d'une substance des signaux, notamment des signaux electriques, caracteristiques de l'activite biologique et/ou chimique de ladite substance |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DE60040651D1 (de) | 1999-02-12 | 2008-12-11 | Emd Serono Res Ct Inc | Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien |
ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
WO2001062298A2 (en) | 2000-02-24 | 2001-08-30 | Philogen S.R.L. | Compositions and methods for treatment of angiogenesis in pathological lesions |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
CA2443903C (en) | 2001-04-13 | 2018-03-20 | Biogen, Inc. | Antibodies to vla-1 |
US7916388B2 (en) | 2007-12-20 | 2011-03-29 | Cymer, Inc. | Drive laser for EUV light source |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
US7371371B2 (en) | 2001-08-13 | 2008-05-13 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
EP1454138B1 (en) * | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2471551C (en) | 2001-12-27 | 2014-09-30 | Glycofi, Inc. | Methods to engineer mammalian-type carbohydrate structures |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
WO2003085119A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia |
DE60333201D1 (de) | 2002-09-12 | 2010-08-12 | Greenovation Biotech Gmbh | Verfahren zur herstellung von proteinen |
PL212899B1 (pl) | 2002-12-16 | 2012-12-31 | Genentech Inc | Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku |
PL211180B1 (pl) | 2002-12-17 | 2012-04-30 | Merck Patent Gmbh | Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków |
US7781197B2 (en) | 2002-12-20 | 2010-08-24 | Greenovation Biotech Gmbh | Transformed bryophyte cell having disrupted endogenous alpha 1,3-fucosyl and beta 1,2-xylosyl transferase encoding nucleotide sequences for the production of heterologous glycosylated proteins |
US20040248262A1 (en) | 2003-01-22 | 2004-12-09 | Koeberl Dwight D. | Constructs for expressing lysomal polypeptides |
NZ603037A (en) | 2003-01-22 | 2014-05-30 | Roche Glycart Ag | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
AU2004239065B2 (en) | 2003-05-14 | 2008-05-15 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
CA2550998A1 (en) | 2003-12-22 | 2005-07-14 | Chiron Corporation | Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders |
WO2005091956A2 (en) | 2004-03-05 | 2005-10-06 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验*** |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
BRPI0510674A (pt) | 2004-07-15 | 2007-12-26 | Xencor Inc | variantes fc otimizadas |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
CA2587572A1 (en) | 2004-11-24 | 2006-06-01 | Schering Corporation | Dap-10 and uses thereof |
EP2395026B1 (en) | 2005-02-08 | 2018-01-24 | The Chemo-Sero-Therapeutic Research Institute | Method for improving antibody |
CA2601858A1 (en) * | 2005-03-25 | 2006-09-28 | Glycart Biotechnology Ag | Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function |
US8455625B2 (en) * | 2005-05-11 | 2013-06-04 | Philogen S.P.A. | Fusion protein of antibody L19 against fibronectin ED-B and interleukin 12 |
EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
WO2007128563A1 (en) | 2006-05-08 | 2007-11-15 | Philogen Spa | Antibody-targeted cytokines for therapy |
DE102006031143A1 (de) | 2006-07-04 | 2008-01-24 | Merck Patent Gmbh | Fluortenside |
CA2656700A1 (en) * | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
KR101248252B1 (ko) | 2006-11-28 | 2013-03-27 | 한올바이오파마주식회사 | 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도 |
CA2687117A1 (en) * | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
AU2008278803A1 (en) | 2007-07-25 | 2009-01-29 | Astrazeneca Ab | Targeted binging agents directed to KDR and uses thereof - 035 |
US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
WO2009085462A1 (en) | 2007-12-19 | 2009-07-09 | Centocor, Inc. | Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
ATE548052T1 (de) | 2008-01-17 | 2012-03-15 | Philogen Spa | Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler |
BRPI0911427A2 (pt) * | 2008-04-10 | 2015-11-17 | Ibc Pharmaceuticals | complexo por dnl (dock and lock) de anticorpo-citocina, uso de uma composição farmaceutica. |
CN102026669B (zh) * | 2008-05-13 | 2012-10-24 | 莫尔梅德股份有限公司 | 缀合物在制备用于治疗间皮瘤的药物中的用途 |
JP5398712B2 (ja) | 2008-06-26 | 2014-01-29 | 眞一 金丸 | 鼓膜または外耳道再生剤 |
CA2749539C (en) | 2009-01-21 | 2022-07-19 | Amgen Inc. | Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases |
MX337590B (es) * | 2009-01-29 | 2016-03-11 | Medimmune Llc | Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias. |
CA2756393C (en) * | 2009-03-24 | 2017-06-20 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Anti-mesothelin antibodies |
WO2010117448A2 (en) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
EP2448599A1 (en) | 2009-06-30 | 2012-05-09 | Philogen S.p.A. | Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer |
JP5322227B2 (ja) | 2009-07-13 | 2013-10-23 | Kddi株式会社 | 光直交周波数分割多重通信装置及び通信方法 |
KR101588598B1 (ko) * | 2009-08-17 | 2016-01-29 | 로슈 글리카트 아게 | 표적화된 면역접합체 |
BR112012003983A2 (pt) * | 2009-08-31 | 2021-09-14 | Roche Glycart Ag | Molecula de ligação abm moleculas de ligação de antigenos abm variante polipeptideo isolado molecula de ligação de antigeneos humanizada anticorpo polinucleotideo isolado composição vetor celula hospedeira metodo de produção de abm metodo de indução da lise celular de tumor, metodo de diagnostico de doença em pacientes que possuem um cancer metodo de aumento de tempo de sobrevivencia em pacientes que possuem um cancer metodo de indução em pacientes de regressão de um motor uso abm e invenção |
PT2483310E (pt) | 2009-09-29 | 2014-10-07 | Roche Glycart Ag | Anticorpos bi-específicos agonistas do receptor de morte |
UA113712C2 (xx) | 2010-08-13 | 2017-02-27 | Антитіло до fap і способи його застосування | |
JP5841149B2 (ja) | 2010-08-13 | 2016-01-13 | ロシュ グリクアート アーゲー | 抗テネイシンca2抗体及び使用の方法 |
CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
JP5700778B2 (ja) | 2010-11-17 | 2015-04-15 | ニチハ株式会社 | 胴縁留め付け部材及びそれを用いた施工構造 |
JP5740260B2 (ja) | 2011-02-02 | 2015-06-24 | 株式会社日立ソリューションズ | セキュリティポリシー管理サーバ、セキュリティ監視システム |
JP5878182B2 (ja) | 2011-02-10 | 2016-03-08 | ロシュ グリクアート アーゲー | ミュータントインターロイキン−2ポリペプチド |
ES2657856T3 (es) | 2011-03-02 | 2018-03-07 | Roche Glycart Ag | Anticuerpos CEA |
DK2691417T3 (en) | 2011-03-29 | 2018-11-19 | Roche Glycart Ag | ANTIBODY FC VARIANTS |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
JP6159724B2 (ja) | 2011-08-23 | 2017-07-05 | ロシュ グリクアート アーゲー | T細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法 |
RS57744B1 (sr) | 2011-08-23 | 2018-12-31 | Roche Glycart Ag | Bispecifični antigen vezujući molekuli |
US20130060011A1 (en) | 2011-08-23 | 2013-03-07 | Peter Bruenker | Fc-free antibodies comprising two fab fragments and methods of use |
LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
SG11201407580YA (en) | 2012-08-07 | 2014-12-30 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
MX370283B (es) | 2014-02-06 | 2019-12-09 | Hoffmann La Roche | Proteinas de fusion de interleucina-2 y usos de las mismas. |
SG11201701157UA (en) | 2014-08-29 | 2017-03-30 | Hoffmann La Roche | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
CN108290954B (zh) | 2015-12-09 | 2022-07-26 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于降低抗药物抗体形成 |
JP6966740B2 (ja) | 2018-10-23 | 2021-11-17 | Tdk株式会社 | ショットキーバリアダイオード |
-
2012
- 2012-02-07 EA EA201892619A patent/EA201892619A1/ru unknown
- 2012-04-26 UA UAA201313703A patent/UA115034C2/uk unknown
- 2012-04-26 JP JP2014506852A patent/JP5972355B2/ja active Active
- 2012-04-26 WO PCT/EP2012/057587 patent/WO2012146628A1/en active Application Filing
- 2012-04-26 MY MYPI2013702028A patent/MY164661A/en unknown
- 2012-04-26 SG SG2013076013A patent/SG194465A1/en unknown
- 2012-04-26 CN CN201280032533.7A patent/CN103649114B/zh active Active
- 2012-04-26 KR KR1020137028345A patent/KR101715445B1/ko active IP Right Grant
- 2012-04-26 CN CN201810315322.3A patent/CN108503713A/zh active Pending
- 2012-04-26 PL PL12717674T patent/PL2702074T3/pl unknown
- 2012-04-26 MX MX2015015971A patent/MX354868B/es unknown
- 2012-04-26 PT PT12717674T patent/PT2702074T/pt unknown
- 2012-04-26 ES ES12717674T patent/ES2707297T3/es active Active
- 2012-04-26 HU HUE12717674A patent/HUE042187T2/hu unknown
- 2012-04-26 RS RS20190095A patent/RS58295B1/sr unknown
- 2012-04-26 EA EA201301208A patent/EA025851B1/ru not_active IP Right Cessation
- 2012-04-26 US US13/457,039 patent/US9447159B2/en active Active
- 2012-04-26 PE PE2018000424A patent/PE20181202A1/es unknown
- 2012-04-26 DK DK12717674.1T patent/DK2702074T3/en active
- 2012-04-26 AU AU2012247548A patent/AU2012247548B2/en active Active
- 2012-04-26 CA CA2831008A patent/CA2831008C/en active Active
- 2012-04-26 AR ARP120101449 patent/AR086075A1/es unknown
- 2012-04-26 EP EP12717674.1A patent/EP2702074B1/en active Active
- 2012-04-26 BR BR112013025127A patent/BR112013025127A2/pt not_active Application Discontinuation
- 2012-04-26 SG SG10201606300XA patent/SG10201606300XA/en unknown
- 2012-04-26 LT LTEP12717674.1T patent/LT2702074T/lt unknown
- 2012-04-26 TR TR2018/18974T patent/TR201818974T4/tr unknown
- 2012-04-26 MX MX2013012413A patent/MX2013012413A/es not_active Application Discontinuation
- 2012-04-26 SI SI201231506T patent/SI2702074T1/sl unknown
- 2012-04-26 MY MYPI2017000406A patent/MY181961A/en unknown
- 2012-04-26 PE PE2013002424A patent/PE20141019A1/es active IP Right Grant
- 2012-04-26 EA EA201600418A patent/EA034251B1/ru not_active IP Right Cessation
- 2012-04-27 TW TW101115308A patent/TWI592424B/zh active
-
2013
- 2013-09-10 ZA ZA2013/06820A patent/ZA201306820B/en unknown
- 2013-09-24 CR CR20130480A patent/CR20130480A/es unknown
- 2013-10-21 IL IL22900613A patent/IL229006B/en active IP Right Grant
- 2013-10-22 CL CL2013003064A patent/CL2013003064A1/es unknown
- 2013-10-28 EC ECSP13013002 patent/ECSP13013002A/es unknown
- 2013-10-29 CO CO13256654A patent/CO6801645A2/es unknown
-
2014
- 2014-06-12 HK HK19101880.0A patent/HK1259474A1/zh unknown
-
2016
- 2016-01-15 US US14/996,893 patent/US10316104B2/en active Active
- 2016-04-15 JP JP2016081782A patent/JP6559607B2/ja active Active
- 2016-07-01 US US15/200,507 patent/US10202464B2/en active Active
-
2017
- 2017-04-12 AU AU2017202437A patent/AU2017202437B2/en active Active
-
2018
- 2018-07-27 JP JP2018140801A patent/JP2018198606A/ja active Pending
- 2018-12-10 US US16/215,375 patent/US20190322763A1/en not_active Abandoned
-
2019
- 2019-01-18 HR HRP20190118TT patent/HRP20190118T1/hr unknown
- 2019-06-03 US US16/430,301 patent/US11130822B2/en active Active
- 2019-09-26 IL IL26968219A patent/IL269682A/en unknown
-
2021
- 2021-09-27 US US17/486,766 patent/US20220242971A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201892619A1 (ru) | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 | |
PH12020551317A1 (en) | Anti-cd73 antibodies and methods of use thereof | |
MX2019014695A (es) | Proteinas de fusion de interleucina-2 y usos de las mismas. | |
TW201613954A (en) | Interleukin-10 fusion proteins and uses thereof | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
CY1117842T1 (el) | Πολυπεπτιδια μεταλλαγμενης il-2 | |
NZ725079A (en) | Transgene genetic tags and methods of use | |
MD4716B1 (ru) | Антитела анти-LAG3 и антигенсвязывающие фрагменты | |
MX2021001494A (es) | Anticuerpos dkk1 y metodos de uso. | |
PH12020551907A1 (en) | Antagonizing cd73 antibody | |
PH12014502767A1 (en) | Interleukin-2 fusion proteins and uses thereof | |
EA202191380A1 (ru) | Антитела к альфа-синуклеину и их применение | |
MY171100A (en) | Anti-ceacam5 antibodies and uses thereof | |
EA201491470A1 (ru) | Композиции фактора viii и способы получения и использования подобных | |
TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
EA201991059A1 (ru) | МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ | |
UA118354C2 (uk) | Антитіло до рецептора колонієстимулювального фактора (кфс-1r) | |
MX2011008763A (es) | Peptidos foxm1 y vacunas que contienen los mismos. | |
PH12020551019A1 (en) | IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
MX2022002315A (es) | Anticuerpos anti-cd96 y sus metodos de uso. | |
PH12015500771A1 (en) | Novel fc gamma receptor iib variants | |
NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
MX355759B (es) | Peptidos topk y vacunas que incluyen los mismos. |